Login / Signup

Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis.

Ahmad Adebayo IrekeolaNurul Adila MalekYusuf WadaNazri MustaffaNur Izat MuhamadRafidah Hanim Shueb
Published in: PloS one (2021)
Known for its high genetic diversity and variation in genotypic presence in different regions of the world, hepatitis C virus (HCV) is estimated to infect about 71 million people globally. Selection of an appropriate therapeutic regimen largely depends on the identification of the genotype responsible for the infection. This systematic review and meta-analysis was conducted to provide a comprehensive view of HCV genotype and subtype distribution in Southeast Asia (SEA). The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). We searched five databases without year and language restrictions. Data from 90 eligible studies involving 15,089 genotypes and 9,646 subtypes representing 10 SEA countries were analyzed. The pooled estimates showed that genotype 1 (46.8%) [95% CI, 43.2-50.4; I2 = 92.77%; p < 0.001] was the most dominant HCV genotype in the region, followed by genotype 3 (23.1%) [95% CI, 19.4-27.2; I2 = 93.03%; p < 0.001], genotype 6 (16.5%) [95% CI, 13.8-19.6], genotype 2 (4.6%) [95% CI, 3.5-5.9], genotype 4 (1.1%) [95% CI, 0.7-1.5] and genotype 5 (0.8%) [95% CI, 0.4-1.3]. Philippines had the highest prevalence of genotypes 1 and 2. Genotype 6 became more prevalent after year 2000. Over 40 different subtypes were identified, with subtypes 1b (26.3%), 1a (21.3%), and 3a (14.3%) being the most prevalent of all the reported subtypes. Although on a global scale, genotype 6 is considered highly prevalent in SEA, evidence from this study reveals that it is the third most prevalent genotype within the region.
Keyphrases
  • hepatitis c virus
  • human immunodeficiency virus
  • systematic review
  • randomized controlled trial
  • risk factors
  • emergency department
  • genetic diversity
  • autism spectrum disorder
  • electronic health record
  • adverse drug